

Personal Information



Jedzada Maneechavakajorn

Address: Rajavithi Hospital

Country: Thailand

Curriculum Vitae

Education:

Graduate Training Education:

- Bsc. (1st class honours) May, 1981, Faculty of Science, Mahidol University, Bangkok, Thailand.
- M.D. (1st class honours) March, 1985, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Postgraduate Training:

April 1, 1985-March 31, 1986:	Rotating externship, Siriraj Hospital, Bangkok, Thailand.
June 1, 1989-May 31, 1992	Resident Training in Internal Medicine, Siriraj Hospital, Bangkok, Thailand.
January 3, 1994-January 3, 1996	Fellowship Training in Medical Oncology, Ramathibodi Hospital, Bangkok, Thailand.

Postgraduate medical employment:

April 1, 1986-May 31, 1989	Medical Staff and Director, Nikhomkumsoi Hospital, Mukdaharn
June 15, 1992-December 31, 1993	Medical Staff, Bangkok Adventist Hospital, Bangkok, Thailand
January 3, 1996-Present	Medical Staff in Oncology Unit, Department of Medical Services, Rajavithi Hospital, Ministry of Public Health, Thailand.

Publication:

1. Maneechavakajorn J. Tumor marker., Textbook of Medical Oncology 2 , 1998; 96-118.
2. Maneechavakajorn J, Cancer of an unknown primary site, Textbook of Medical Oncology 2, 1998; 354-373.
3. Maneechavakajorn J, Ratanatharathorn V, Sirilertrakul S, Jirajarus M, et al. Quality of life, Functional Assessment of Cancer Therapy-General. J Med Assoc Thai 2001; 84: 1430-1442.

4. Maneechavakajorn J, Small cell lung cancer 2006, Rajavithi update medicine, 2006; 209-223.
5. Maneechawakajorn J, Benjawongsathien D. Prognostic role of thyroid transcription factor-1 (TTF-1) in advanced and inoperable adenocarcinoma subtype of lung cancer among Thai patients. J Med Assoc Thai 2014; 97 (Suppl 11):S11-17.
6. Maneechawakajorn J, Suksuperm J. Quality of life in advanced non-small cell lung cancer receiving chemotherapy of platinum combination in old versus new standard chemotherapy regimen. J Med Assoc Thai 2014; 97(Suppl 11): S69-75.
7. Maneechawakajorn J, Hathaisanguan S. Quality of life achieved by carboplatin plus etoposide as third-line chemotherapy compared with best supportive care in non-small cell lung cancer stage IIIB/IV. J Med Assoc Thai 2016; 99(Suppl 2): S175-81.

Previous appointments/experience

- | | |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 16/7/1998 | Attend “Biostatistic in cancer research and data management” at Cancer center of U. Michigan, Ann Arber, Michigan |
| 22-24/11/1999 | Training “Hospice and palliative care in cancer patient” at International Institute of Hospice Studies and the Finders University of South Australia, Adeles, Australia |

Previous experience in clinical trials and type of GCP training received

- | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| BRAVE study, ISEL study, IPASS study, MEC study, Cantarisk study, Cleopatra study, Marrienne study, Masatinib study in GIST, Afatinib study in breast and lung cancer, BRAF melanoma study, etc. | |
| 24/4/2001 | “Good clinical practice training” at Le Royal Meridien President Hotel, Bangkok |